<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093533</url>
  </required_header>
  <id_info>
    <org_study_id>EAGLE</org_study_id>
    <secondary_id>2013-003826-10</secondary_id>
    <nct_id>NCT02093533</nct_id>
  </id_info>
  <brief_title>Eculizumab in Primary MPGN</brief_title>
  <acronym>EAGLE</acronym>
  <official_title>EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexion Pharma Italy s.r.l.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Membranoproliferative glomerulonephritis (MPGN) is the third or fourth leading cause of end
      stage renal disease among the primary glomerulonephritis. Hyperactivation of the alternative
      complement pathway and familial forms for all types of MPGN have been reported suggesting
      that genetic abnormalities may play a predisposing role to the disease. In recent case
      reports Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the
      membrane attack complex ,is a safe and effective therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24hours proteinuria</measure>
    <time_frame>Changes from baseline at week 1,12,24,36,48 and 72.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal complement complex (sC5b-9) levels</measure>
    <time_frame>Changes from baseline at 1,2, 3, 4,12,24,36,48,52,56,60 and 72 week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR) measured by iohexol plasma clearance and estimated.</measure>
    <time_frame>Changes from Baseline at 1,24, 48 and 72 week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression.</measure>
    <time_frame>Up 72 week.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with Adverse Events as a measure of safety.</measure>
    <time_frame>Participants will be followed for the duration of the study, an expected average of 72 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Membranoproliferative Glomerulonephritis</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient Body weight ≥40 kg: initial phase 900 mg weekly x 4 and maintenance phase 1200 mg at week 5; then 1200 mg every 2 weeks Patient Body weight 30 - &lt;40 kg : initial phase 600 mg weekly x 2 and maintenance phase 900 mg at week 3; then 900 mg every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven primary MPGN

          -  Creatinine clearance &gt;20 ml/min per 1.73m2

          -  24-hour proteinuria persistently exceeding 3,5g in adults or exceeding 40mg/h/m2 in
             children (or exceeding 2mg protein/mg creatinine in children spot urine samples)

          -  Persistently low C3 levels in at least two consecutive evaluations

          -  Persistently high sC5b9 levels (&gt;1000 ng/ml) in at least two previous consecutive
             evaluations

          -  Written informed consent (by parents or tutors if underage)

        Exclusion Criteria:

          -  Age ≥75 years

          -  Secondary MPGN (evidence of infection, immunological disease including vasculitis,
             systemic diseases and proliferative disorders)

          -  Evidence at kidney biopsy evaluation of severe chronic histological changes that very
             unlikely could benefit of eculizumab therapy

          -  Concomitant steroid or immunosuppressive therapy for immuno-mediated disease

          -  Pregnancy or lactating

          -  Childbearing potential without effective contraception

          -  Any clinically relevant condition that might affect completion of the study
             participation and/or confound study results

          -  Inability to understand the potential risks and benefits of the study

          -  Legal incapacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedale Pediatrico &quot;Giovanni XXIII&quot; - U:O Nefrologia</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/IRCCS IRFMN - Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola -Malpighi - U.O.S. Nefrologia e dialisi pediatrica</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico &quot;G.Martino&quot; - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario di Padova - U.O. Nefrologia Pediatrica</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Centrale</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico &quot;Federico II&quot; - U.O. Nefrologia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.I. Columbus-Università Cattolica del S.Cuore - UOC Nefrologia e Dialisi</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico &quot;Bambin Gesù&quot; - U.O. Nefrologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero O.I.R.M. &quot;Sant'Anna&quot; - U.O. Nefrologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Santa Chiara&quot; - U.O. Nefrologia</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cà Foncello - U.O. Nefrologia</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Membranoproliferative glomerulonephritis</keyword>
  <keyword>Nephrotic syndrome</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Alternative complement pathway</keyword>
  <keyword>Complement inhibition</keyword>
  <keyword>Eculizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranoproliferative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

